RU98107896A - NEW AFFINE LIGANDS AND THEIR APPLICATION - Google Patents
NEW AFFINE LIGANDS AND THEIR APPLICATIONInfo
- Publication number
- RU98107896A RU98107896A RU98107896/12A RU98107896A RU98107896A RU 98107896 A RU98107896 A RU 98107896A RU 98107896/12 A RU98107896/12 A RU 98107896/12A RU 98107896 A RU98107896 A RU 98107896A RU 98107896 A RU98107896 A RU 98107896A
- Authority
- RU
- Russia
- Prior art keywords
- group
- matrix
- general formula
- affinity
- ligand
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title claims 50
- 239000011159 matrix material Substances 0.000 claims 64
- 230000027455 binding Effects 0.000 claims 57
- 125000004432 carbon atoms Chemical group C* 0.000 claims 19
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 15
- 239000002253 acid Substances 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 10
- 125000003277 amino group Chemical group 0.000 claims 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000004430 oxygen atoms Chemical group O* 0.000 claims 8
- 108010078762 Protein Precursors Proteins 0.000 claims 7
- 102000014961 Protein Precursors Human genes 0.000 claims 7
- 239000000969 carrier Substances 0.000 claims 7
- 239000000463 material Substances 0.000 claims 7
- 125000001624 naphthyl group Chemical group 0.000 claims 7
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims 7
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 125000004434 sulfur atoms Chemical group 0.000 claims 6
- 239000011230 binding agent Substances 0.000 claims 5
- 239000011521 glass Substances 0.000 claims 5
- 229920000620 organic polymer Polymers 0.000 claims 5
- 239000000377 silicon dioxide Substances 0.000 claims 5
- 108090001061 Insulin Proteins 0.000 claims 4
- 102000004877 Insulin Human genes 0.000 claims 4
- 238000002955 isolation Methods 0.000 claims 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 4
- 238000000746 purification Methods 0.000 claims 4
- 238000000926 separation method Methods 0.000 claims 4
- 235000012239 silicon dioxide Nutrition 0.000 claims 4
- -1 β-phenylethyl group Chemical group 0.000 claims 4
- WITMXBRCQWOZPX-UHFFFAOYSA-N 1-phenylpyrazole Chemical group C1=CC=NN1C1=CC=CC=C1 WITMXBRCQWOZPX-UHFFFAOYSA-N 0.000 claims 3
- 229920000936 Agarose Polymers 0.000 claims 3
- IOJUPLGTWVMSFF-UHFFFAOYSA-N Benzothiazole Chemical group C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims 3
- BCMCBBGGLRIHSE-UHFFFAOYSA-N Benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims 3
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 claims 3
- 108090001122 Immunoglobulin A Proteins 0.000 claims 3
- 229940099472 Immunoglobulin A Drugs 0.000 claims 3
- 108090001095 Immunoglobulin G Proteins 0.000 claims 3
- 229940027941 Immunoglobulin G Drugs 0.000 claims 3
- 102000004851 Immunoglobulin G Human genes 0.000 claims 3
- 108090001096 Immunoglobulin M Proteins 0.000 claims 3
- 102000004854 Immunoglobulin M Human genes 0.000 claims 3
- 108060003951 Immunoglobulins Proteins 0.000 claims 3
- 102000018358 Immunoglobulins Human genes 0.000 claims 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 3
- 150000001720 carbohydrates Chemical class 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 229910044991 metal oxide Inorganic materials 0.000 claims 3
- 150000004706 metal oxides Chemical class 0.000 claims 3
- 238000011002 quantification Methods 0.000 claims 3
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims 2
- 239000004215 Carbon black (E152) Substances 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 2
- 230000003213 activating Effects 0.000 claims 2
- 125000004442 acylamino group Chemical group 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 2
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 238000009833 condensation Methods 0.000 claims 2
- 230000005494 condensation Effects 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 150000002391 heterocyclic compounds Chemical class 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- DPFYBZWSVVKNPZ-AQWIXGDGSA-N (3S,4S,6R)-2-[[(2R,4R,5R)-3,5-dihydroxy-4-methoxy-6-(methoxymethyl)oxan-2-yl]methoxymethyl]-6-ethyloxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)C(O)[C@@H](CC)OC1COC[C@@H]1C(O)[C@H](OC)[C@H](O)C(COC)O1 DPFYBZWSVVKNPZ-AQWIXGDGSA-N 0.000 claims 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 claims 1
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 claims 1
- BLMFNYXTSPNJSB-UHFFFAOYSA-N 1-chloro-4-[2-[3-(4-chlorophenyl)prop-1-en-2-ylsulfonyl]prop-2-enyl]benzene Chemical compound C1=CC(Cl)=CC=C1CC(=C)S(=O)(=O)C(=C)CC1=CC=C(Cl)C=C1 BLMFNYXTSPNJSB-UHFFFAOYSA-N 0.000 claims 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N 2-hydroxyethyl 2-methylacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims 1
- 239000004593 Epoxy Substances 0.000 claims 1
- 102100009906 F7 Human genes 0.000 claims 1
- 108010023321 Factor VII Proteins 0.000 claims 1
- 102000002265 Human Growth Hormone Human genes 0.000 claims 1
- 108010000521 Human Growth Hormone Proteins 0.000 claims 1
- 239000000854 Human Growth Hormone Substances 0.000 claims 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N Sulfuryl chloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims 1
- 238000001042 affinity chromatography Methods 0.000 claims 1
- 125000005263 alkylenediamine group Chemical group 0.000 claims 1
- 125000004429 atoms Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Chemical group 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000006143 cell culture media Substances 0.000 claims 1
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000003700 epoxy group Chemical group 0.000 claims 1
- 229940012413 factor VII Drugs 0.000 claims 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 1
- 238000005755 formation reaction Methods 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N iodine atom Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000011049 pearl Substances 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 229920002401 polyacrylamide Polymers 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 108010013773 recombinant FVIIa Proteins 0.000 claims 1
- 229940068953 recombinant FVIIa Drugs 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000542 sulfonic acid group Chemical group 0.000 claims 1
- 125000004962 sulfoxyl group Chemical group 0.000 claims 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims 1
- 0 CC1*=C(C)*=C(C*)C1 Chemical compound CC1*=C(C)*=C(C*)C1 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Cc1ccccc1 Chemical compound Cc1ccccc1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
Claims (1)
где R1 представляет атом водорода, алкильную группу, содержащую 1-6 атомов углерода, гидроксиалкильную группу, содержащую 1-6 атомов углерода, циклогексильную группу, аминогруппу, фенильную группу, нафтильную группу, 1-фенилпиразольную группу, индазольную группу, бензтиазольную группу, бензоксазольную группу или бензимидазольную группу, где каждое из бензольного, нафталинового, 1-фенилпиразольного, индазольного, бензтиазольного, бензоксазольного или бензимидазольного колец необязательно замещено одним или несколькими заместителями, независимо выбранными из группы, включающей алкильные группы, содержащие, 1-6 атомов углерода; алкоксигруппы, содержащие 1-6 атомов углерода; ацилокси- или ациламино-группы, содержащие 1-6 атомов углерода; амино-группы, гидроксильные группы; карбоксильные группы; сульфокислотные группы; карбамоильные группы; сульфамоильные группы; алкилсульфонильные группы, содержащие, 1-6 атомов углерода; или атомы галогена;
Y представляет атом кислорода, атом серы, или группу N-R2;
Z представляет атом кислорода, атом серы, или группу N-R3;
каждый из R2 и R3 независимо представляет атом водорода; алкильную группу, содержащую 1-6 атомов углерода; гидроксиалкильную группу, содержащую 1-6 атомов углерода; бензильную группу или β-фенилэтильную группу;
каждый из R4, R5 и R6 независимо представляет атом водорода; гидроксильную группу; алкильную группу, содержащую 1-6 атомов углерода; алкокси-группу, содержащую 1-6 атомов углерода, аминогруппу; ацилокси- или ациламино-группу, содержащую 1-6 атомов углерода; карбоксильную группу, сульфоксильную группу, карбамоильную или сульфамоильную группу; алкилсульфонильную группу, содержащую 1-6 атомов углерода; или атом галогена;
один из символов X представляет атом азота, а другой символ X представляет атом азота или атом углерода, несущие атом хлора или циано-группу;
Q представляет бензольное, нафталиновое, 1-фенилпиразольное, индазольное, бензтиазольное, бензоксазольное, или бензимидазольное кольцо;
n представляет целое число от 0 до 6;
p представляет целое число от 0 до 20; и где лиганд связан с матрицей-носителем в положении A необязательно посредством спейсерной группы, расположенной между матрицей и лигандом, при условии, что формула (a) не включает продукты реакции соединений 4-хлор-2,6-ди(фениламино)-1,3,5-триазин-3'-сульфокислоты, 4-хлор-2,6-ди(фениламино)-1,3,5-триазин-3',2''-дисульфокислоты, и 4-хлор-2-(4''-аминофениламино)-1,3,5-триазин-3',2''-дисульфокислоты с Декстраном Т 500.1. The affinity ligand-matrix conjugates containing the ligand of the general formula (a):
where R 1 represents a hydrogen atom, an alkyl group containing 1-6 carbon atoms, a hydroxyalkyl group containing 1-6 carbon atoms, a cyclohexyl group, an amino group, a phenyl group, a naphthyl group, a 1-phenylpyrazole group, an indazole group, a benzothiazole group, a benzoxazole a group or benzimidazole group, where each of the benzene, naphthalene, 1-phenylpyrazole, indazole, benzthiazole, benzoxazole or benzimidazole rings is optionally substituted with one or more substituents, not pendently selected from the group consisting of alkyl groups containing 1-6 carbon atoms; alkoxy groups containing 1-6 carbon atoms; acyloxy or acylamino groups containing 1-6 carbon atoms; amino groups, hydroxyl groups; carboxyl groups; sulfonic acid groups; carbamoyl groups; sulfamoyl groups; alkylsulfonyl groups containing 1-6 carbon atoms; or halogen atoms;
Y represents an oxygen atom, a sulfur atom, or a group NR 2 ;
Z represents an oxygen atom, a sulfur atom, or a group NR 3 ;
each of R 2 and R 3 independently represents a hydrogen atom; an alkyl group containing 1-6 carbon atoms; hydroxyalkyl group containing 1-6 carbon atoms; a benzyl group or a β-phenylethyl group;
each of R 4 , R 5 and R 6 independently represents a hydrogen atom; hydroxyl group; an alkyl group containing 1-6 carbon atoms; alkoxy group containing 1-6 carbon atoms, an amino group; an acyloxy or acylamino group containing 1-6 carbon atoms; a carboxyl group, a sulfoxyl group, a carbamoyl or sulfamoyl group; alkylsulfonyl group containing 1-6 carbon atoms; or a halogen atom;
one of the symbols X represents a nitrogen atom, and the other symbol X represents a nitrogen atom or a carbon atom carrying a chlorine atom or a cyano group;
Q represents a benzene, naphthalene, 1-phenylpyrazole, indazole, benzthiazole, benzoxazole, or benzimidazole ring;
n represents an integer from 0 to 6;
p represents an integer from 0 to 20; and where the ligand is bound to the support matrix in position A, optionally via a spacer group located between the matrix and the ligand, provided that formula (a) does not include reaction products of compounds 4-chloro-2,6-di (phenylamino) -1, 3,5-triazine-3'-sulfonic acid, 4-chloro-2,6-di (phenylamino) -1,3,5-triazin-3 ', 2''- disulfonic acid, and 4-chloro-2- (4 '' -aminophenylamino) -1,3,5-triazin-3 ', 2''- disulfonic acids with Dextran T 500.
-T-[-L-V-]m- (b)
где T представляет атом кислорода, атом серы, или группу N-R7, где R7 представляет атом водорода или алкильную группу, содержащую 1-6 атомов углерода;
V представляет атом кислорода, атом серы, группу -COO-, группу CONH или группу NHCO или группу -PO3H-, группу NH-арилен-SO2-CH2-CH2, или группу N-R8, где R8 представляет атом водорода или алкильную группу, содержащую 1-6 атомов углерода;
L представляет необязательно замещенную углеводородную связь, содержащую от 2 до 20 атомов углерода; и
m = 0 или 1.2. The affinity ligand-matrix conjugates according to claim 1, wherein the optional spacer group located between the ligand and the matrix is represented by the general formula (b):
-T - [- LV-] m - (b)
where T represents an oxygen atom, a sulfur atom, or a group NR 7 , where R 7 represents a hydrogen atom or an alkyl group containing 1-6 carbon atoms;
V represents an oxygen atom, a sulfur atom, a —COO— group, a CONH group or an NHCO group or a —PO 3 H— group, an NH-arylene-SO 2 —CH 2 —CH 2 group, or an NR 8 group, where R 8 represents an atom hydrogen or an alkyl group containing 1-6 carbon atoms;
L represents an optionally substituted hydrocarbon bond containing from 2 to 20 carbon atoms; and
m = 0 or 1.
где: R1, Y, Z, R2, R3, R4, R5, R6, X, Q, n и p определены выше;
T представляет атом кислорода, атом серы, или группу N-R7;
V представляет атом кислорода, атом серы, группу -COO-, группу CONH, или группу NHCO или группу -PO3H-, группу NH-арилен-SO2-CH2-CH2, или группу N-R8,
каждый из R7 и R8 независимо представляет атом водорода или алкильную группу, содержащую 1-6 атомов углерода;
L представляет необязательно замещенную углеводородную связь, содержащую от 2 до 20 атомов углерода; и
m = 0 или 1; и
M представляет остаток матрицы-носителя.3. The affinity ligand-matrix conjugates, which are represented by the general formula (I):
where: R 1 , Y, Z, R 2 , R 3 , R 4 , R 5 , R 6 , X, Q, n and p are as defined above;
T represents an oxygen atom, a sulfur atom, or a group NR 7 ;
V represents an oxygen atom, a sulfur atom, a —COO— group, a CONH group, or an NHCO group or a —PO 3 H— group, an NH-arylene-SO 2 —CH 2 —CH 2 group, or an NR 8 group,
each of R 7 and R 8 independently represents a hydrogen atom or an alkyl group containing 1-6 carbon atoms;
L represents an optionally substituted hydrocarbon bond containing from 2 to 20 carbon atoms; and
m is 0 or 1; and
M represents the remainder of the carrier matrix.
i)
ii)
iii)
iv)
v)
vi)
vii)
viii)
где M определен выше.25. The affinity ligand-matrix conjugates according to any one of the preceding paragraphs, selected from:
i)
ii)
iii)
iv)
v)
vi)
vii)
viii)
where M is defined above.
где символы X имеют значения, указанные выше в любом из предыдущих пунктов, а W обозначает атом галогена
(i) с соединением общей формулы (III):
R1-(CH2)p-Y-H (III)
где символы R1, p и Y являются такими, как они определены в любом из предыдущих пунктов;
(ii) с соединением общей формулы (IV):
где символы R4, R5, R6, Q, Z и n являются такими, как они определены в любом из предыдущих пунктов; и
(iii) либо с необязательно дериватезированной матрицей-носителем общей формулы (V):
H-T-[-L-V-]m-M (V)
где символы L, M, V, T и m являются такими, как они определены в любом из предыдущих пунктов.26. A method for producing new affinity ligand-matrix conjugates according to any one of the preceding paragraphs, comprising reacting, in any order, a halogen-containing heterocyclic compound of the general formula (II):
where the symbols X have the meanings indicated above in any of the preceding paragraphs, and W denotes a halogen atom
(i) with a compound of general formula (III):
R 1 - (CH 2 ) p -YH (III)
where the symbols R 1 , p and Y are as defined in any of the preceding paragraphs;
(ii) with a compound of general formula (IV):
where the symbols R 4 , R 5 , R 6 , Q, Z and n are as defined in any of the preceding paragraphs; and
(iii) either with an optionally derivatized carrier matrix of general formula (V):
HT - [- LV-] m -M (V)
where the characters L, M, V, T, and m are as defined in any of the preceding paragraphs.
(i) с соединением общей формулы (III) по п.26,
(ii) с соединением общей формулы (IV) по п.26, и
(iii) со связывающим звеном общей формулы (VI)
H-T-L-V-H (VI)
где символы L, V и T являются такими, как они определены в любом из предыдущих пунктов с получением соединения общей формулы (VII)
где R1, R4, R5, R6, T, Q, L, V, X, Y, Z, m, n и p являются такими, как они определены в любом из предыдущих пунктов, и последующей реакцией соединения общей формулы с (VII) матрицей-носителем.27. A method of producing new affinity ligand-matrix conjugates according to any one of the preceding paragraphs, comprising reacting, in any order, a halogen-containing heterocyclic compound of the general formula (II) according to claim 26:
(i) with a compound of general formula (III) according to claim 26,
(ii) with a compound of general formula (IV) according to claim 26, and
(iii) with a linker of the general formula (VI)
HTLVH (VI)
where the symbols L, V and T are as defined in any of the preceding paragraphs to obtain the compounds of General formula (VII)
where R 1 , R 4 , R 5 , R 6 , T, Q, L, V, X, Y, Z, m, n and p are as defined in any of the preceding paragraphs, and the subsequent reaction of the compounds of General formula with (VII) a carrier matrix.
где R1, R4, R5, R6, Q, X, Y, Z, n и p являются такими, как указано выше, а галоген представляет атом фтора, хлора, брома или иода, при условии, что формула (XII) не включает такие соединения, как 4-хлор-2,6-ди(фениламино)-1,3,5-триазин-3'-сульфокислота, 4-хлор-2,6-ди(фениламино)-1,3,5-триазин-3', 2''-дисульфокислота, и 4-хлор-2-(4''-аминофениламино)-1,3,5-триазин-3', 2''-дисульфокислота.28. New affinity ligands of General formula (XII):
where R 1 , R 4 , R 5 , R 6 , Q, X, Y, Z, n and p are as described above, and the halogen represents a fluorine, chlorine, bromine or iodine atom, provided that the formula (XII ) does not include compounds such as 4-chloro-2,6-di (phenylamino) -1,3,5-triazine-3'-sulfonic acid, 4-chloro-2,6-di (phenylamino) -1.3, 5-triazin-3 ', 2''- disulfonic acid, and 4-chloro-2- (4''- aminophenylamino) -1,3,5-triazin-3', 2 '' - disulfonic acid.
где R1, R4, R5, R6, Q, X, Y, Z, m, n и p являются такими, как указано выше; а j представляет целое число от 2 до 20.30. New affinity ligands of General formula (XIII):
where R 1 , R 4 , R 5 , R 6 , Q, X, Y, Z, m, n and p are as described above; and j represents an integer from 2 to 20.
где R1, R4, R5, Q, X, Y, Z, m, n и p являются такими, как указано выше; q=0 или 1, а j - целое число от 2 до 20.32. New affinity ligands of General formula (XIV):
where R 1 , R 4 , R 5 , Q, X, Y, Z, m, n and p are as described above; q = 0 or 1, and j is an integer from 2 to 20.
где R1, R4, R5, R6, L, Q, T, V, X, Y, Z, m, n и p являются такими, как они определены по любому из предыдущих пунктов; R9 представляет атом водорода или алкильную группу, содержащую 1-6 атомов углерода, R10 представляет карбонильную группу, метиленовую группу, группу -NH-CH2-, или группу -S-CH2-.34. New affinity ligands of General formula (VIII):
where R 1 , R 4 , R 5 , R 6 , L, Q, T, V, X, Y, Z, m, n and p are as defined in any one of the preceding paragraphs; R 9 represents a hydrogen atom or an alkyl group containing 1-6 carbon atoms, R 10 represents a carbonyl group, a methylene group, a group —NH — CH 2 -, or a group —S — CH 2 -.
где R1, R4, R5, R6, Q, n и p являются такими, как они определены в предыдущих пунктах, при условии, что формула (XV) не включает соединения 4-хлор-2,6-ди(фенил-амино)-1,3,5-триазин-3'-сульфокислоты, 4-хлор-2,6-ди(фенил-амино)-1,3,5-триазин-3', 2''-дисульфокислоты, и 4-хлор-2-(4''-аминофениламино)-1,3,5-триазин-3',2''-дисульфокислоты.35. New affinity ligands of General formula (XV):
where R 1 , R 4 , R 5 , R 6 , Q, n and p are as defined in the previous paragraphs, provided that the formula (XV) does not include compounds 4-chloro-2,6-di (phenyl -amino) -1,3,5-triazin-3'-sulfonic acid, 4-chloro-2,6-di (phenyl-amino) -1,3,5-triazin-3 ', 2''- disulfonic acid, and 4-chloro-2- (4 '' - aminophenylamino) -1,3,5-triazin-3 ', 2''- disulfonic acids.
где R1, R4, R5, R6, Q, n и p являются такими, как указано выше в любом из предыдущих пунктов, а j - представляет целое число от 2 до 20.36. New affinity ligands of General formula (XVI):
where R 1 , R 4 , R 5 , R 6 , Q, n and p are as described above in any of the preceding paragraphs, and j - represents an integer from 2 to 20.
а j - представляет целое число от 2 до 20.52. New affinity ligands of General formula (XI):
and j represents an integer from 2 to 20.
54. Применение аффинных лигандов по любому из предыдущих пунктов для получения конъюгатов "аффинный лиганд - матрица".53. Affinity ligands according to any one of paragraphs.28 to 51, selected from the group including:
54. The use of affinity ligands according to any one of the preceding paragraphs for the preparation of affinity ligand-matrix conjugates.
где лиганд присоединен к матрице - носителю в положении (A) необязательно посредством спейсерной группы, представленной общей формулой (b), определенной выше.68. The application of paragraph 61, where the conjugates "affinity ligand matrix" includes a ligand selected from the following ligands:
where the ligand is attached to the matrix carrier in position (A) optionally via a spacer group represented by general formula (b) as defined above.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9519197.9A GB9519197D0 (en) | 1995-09-20 | 1995-09-20 | Novel affinity ligands and their use |
GB9519197,9 | 1995-09-20 | ||
GB9519197.9 | 1995-09-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU98107896A true RU98107896A (en) | 2000-02-20 |
RU2175261C2 RU2175261C2 (en) | 2001-10-27 |
Family
ID=10780990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU98107896/12A RU2175261C2 (en) | 1995-09-20 | 1996-09-19 | Novel affine ligands and their application |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0959975B1 (en) |
JP (1) | JP4824147B2 (en) |
KR (1) | KR100537386B1 (en) |
CN (1) | CN1089617C (en) |
AR (1) | AR003634A1 (en) |
AT (1) | ATE285827T1 (en) |
AU (1) | AU702901B2 (en) |
CA (1) | CA2232626C (en) |
DE (1) | DE69634142T2 (en) |
DK (1) | DK0959975T3 (en) |
ES (1) | ES2236748T3 (en) |
GB (1) | GB9519197D0 (en) |
MY (1) | MY127957A (en) |
RU (1) | RU2175261C2 (en) |
WO (1) | WO1997010887A1 (en) |
ZA (1) | ZA967917B (en) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5760187A (en) * | 1996-02-22 | 1998-06-02 | Mitsui Toatsu Chemicals, Inc. | Purification process of a human growth hormone |
AU729039C (en) * | 1996-08-30 | 2001-08-02 | Upfront Chromatography A/S | Isolation of immunoglobulins |
EP0945447A1 (en) * | 1998-03-27 | 1999-09-29 | Janssen Pharmaceutica N.V. | Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections |
GB9910807D0 (en) * | 1999-05-10 | 1999-07-07 | Prometic Biosciences Limited | Novel detoxification agents and their use |
KR100785360B1 (en) | 1999-09-24 | 2007-12-18 | 얀센 파마슈티카 엔.브이. | Antiviral compositions |
US6153364A (en) * | 1999-12-16 | 2000-11-28 | Eastman Kodak Company | Photographic processing methods using compositions containing stain reducing agent |
US6153365A (en) | 1999-12-16 | 2000-11-28 | Eastman Kodak Company | Photographic processing compositions containing stain reducing agent |
CA2407276A1 (en) * | 2000-04-28 | 2001-11-08 | Accurate Polymers, Ltd. | Simulated activity of protein a displayed by ligands attached to a cellulose bead surface |
US6440651B1 (en) | 2000-10-05 | 2002-08-27 | Eastman Kodak Company | Concentrated photographic fixer additive and fixing compositions and method of photographic processing |
US6288227B1 (en) | 2000-10-05 | 2001-09-11 | Eastman Kodak Company | Solublized 2,6-dinaphthylaminotriazines |
US6943162B2 (en) | 2001-01-26 | 2005-09-13 | Smithkline Beecham Corporation | Piperazinyltriazines as estrogen receptor modulators |
US7173032B2 (en) * | 2001-09-21 | 2007-02-06 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
GB0224446D0 (en) * | 2002-10-21 | 2002-11-27 | Univ Cambridge Tech | Affinity adsorbents for immunoglobulins |
GB0228724D0 (en) * | 2002-12-09 | 2003-01-15 | Prometic Biosciences Ltd | Multidimensinal libraries |
US7109040B2 (en) * | 2002-12-13 | 2006-09-19 | Agilent Technologies, Inc. | Modular isotope coding approach to proteomic analysis |
US7700743B2 (en) | 2003-07-22 | 2010-04-20 | Millipore Corporation | Immobilised affinity medium and its use in separation |
AU2005216847B2 (en) * | 2004-02-27 | 2010-04-01 | Cytiva Bioprocess R&D Ab | A process for the purification of antibodies |
SE0400501D0 (en) * | 2004-02-27 | 2004-02-27 | Amersham Biosciences Ab | Antibody purification |
SE0401665D0 (en) * | 2004-06-24 | 2004-06-24 | Amersham Biosciences Ab | Purification of immunoglobulins |
GB0416699D0 (en) | 2004-07-27 | 2004-09-01 | Prometic Biosciences Ltd | Prion protein ligands and methods of use |
EP1786787A4 (en) * | 2004-09-03 | 2009-07-22 | Prometic Biosciences Inc | 2,4,6-TRIAMINO-S-TRIAZINE-BASED COMPOUNDS WHICH BIND TO THE TAIL (Fc) PORTION OF IMMUNOGLOBULINS AND THEIR USE |
RU2389552C2 (en) * | 2004-10-21 | 2010-05-20 | Джи-И Хелткер Байо-Сайенсиз АБ | Antibody purification method |
US9187549B2 (en) | 2004-12-23 | 2015-11-17 | Novo Nordisk Healthcare A/G | Reduction of the content of protein contaminants in compositions comprising a vitamin K-dependent protein of interest |
GB0509442D0 (en) * | 2005-05-09 | 2005-06-15 | Prometic Biosciences Ltd | Affinity adsorbents for fibrinogen |
GB0509443D0 (en) * | 2005-05-09 | 2005-06-15 | Prometic Biosciences Ltd | Affinity adsorbents for factor VIII and von willebrand's factor |
GB0509438D0 (en) * | 2005-05-09 | 2005-06-15 | Prometic Biosciences Ltd | Affinity adsorbets for fibrinogen |
BRPI0611811A2 (en) | 2005-06-10 | 2008-12-09 | Prometic Biosciences Ltd | protein binding binders |
US20080220968A1 (en) * | 2005-07-05 | 2008-09-11 | Ge Healthcare Bio-Sciences Ab | [1, 2, 4] Triazolo [1, 5-A] Pyrimidine Derivatives as Chromatographic Adsorbent for the Selective Adsorption of Igg |
GB0604236D0 (en) | 2006-03-02 | 2006-04-12 | Prometic Biosciences Ltd | Adsorbents for protein purification |
CA2682333C (en) | 2007-03-28 | 2015-05-05 | Upfront Chromatography A/S | Expanded bed column and disposable chromatography |
US8258295B2 (en) * | 2007-04-30 | 2012-09-04 | Prometic Biosciences Inc. | Triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives |
GB0808908D0 (en) * | 2008-05-16 | 2008-06-25 | Avecia Biolog Ltd | Purification process |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
KR101860057B1 (en) | 2008-05-21 | 2018-05-21 | 어리어드 파마슈티칼스, 인코포레이티드 | Phosphorous derivatives as kinase inhibitors |
WO2010055135A1 (en) * | 2008-11-13 | 2010-05-20 | Novo Nordisk A/S | Process for the purification of human growth hormone polypeptides using affinity resins comprising specific ligands |
JP5781500B2 (en) | 2009-04-15 | 2015-09-24 | アブラクシス バイオサイエンス, エルエルシー | Nanoparticle compositions and methods without prions |
CN102549012B (en) * | 2009-05-07 | 2015-07-01 | 诺维信生物制药丹麦公司 | Method for purifying albumin |
JP2012529522A (en) | 2009-06-10 | 2012-11-22 | アボット・ラボラトリーズ | 2- (1H-pyrazol-4-ylamino) -pyrimidine as a kinase inhibitor |
AU2010278295A1 (en) | 2009-07-28 | 2012-02-23 | Instraction Gmbh | Specific sorbent for binding proteins and peptides, and separation method using the same |
CA2811154C (en) | 2009-09-23 | 2019-01-08 | Albert Einstein College Of Medicine Of Yeshiva University | Prostaglandin transporter inhibitors and uses thereof |
WO2012128353A1 (en) * | 2011-03-24 | 2012-09-27 | 株式会社カネカ | Proteinaceous-substance-binding low-molecular-weight compound |
US9834518B2 (en) | 2011-05-04 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
AU2013204563B2 (en) | 2012-05-05 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
GB2513405A (en) | 2013-04-26 | 2014-10-29 | Adc Biotechnology Ltd | Method of synthesising ADCs using affinity resins |
CN104148018B (en) * | 2013-05-14 | 2018-04-20 | 上海亨臻实业有限公司 | Antibody affinity purification material and application thereof |
EP2918641A1 (en) | 2014-03-13 | 2015-09-16 | Basf Se | Method for purification of antibodies, antibody fragments or engineered variants thereof using specific anthraquinone dye-ligand structures |
GB201419185D0 (en) | 2014-10-28 | 2014-12-10 | Adc Biotechnology Ltd | Method of synthesising ADCs using affinity resin |
GB201419184D0 (en) | 2014-10-28 | 2014-12-10 | Adc Biotechnology Ltd | Method of synthesising biomolecule-effector/reporter-conjugates using affinity resins |
RU2627849C1 (en) * | 2016-07-22 | 2017-08-14 | Игорь Анатольевич Мнушкин | Method for gas flow separation into single components or fractions |
RU2626354C9 (en) * | 2016-07-25 | 2017-10-04 | Игорь Анатольевич Мнушкин | Method of gas flow separation into single components or fractions |
CN109354600B (en) * | 2018-11-29 | 2021-08-10 | 浙江海洋大学 | Preparation method of taurine modified novel Alaska cod multifunctional peptide |
CN113527284A (en) * | 2021-07-16 | 2021-10-22 | 东莞市顶盛环保科技有限公司 | Environment-friendly multifunctional material containing diester group s-triazine derivative and preparation method and application thereof |
CN113563324A (en) * | 2021-07-22 | 2021-10-29 | 东莞市顶盛环保科技有限公司 | Environment-friendly multifunctional material containing ester group s-triazine, and preparation method and application thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3726019A1 (en) * | 1987-08-05 | 1989-02-16 | Boehringer Mannheim Gmbh | METHOD FOR SEPARATING AND PURIFYING T-PA |
-
1995
- 1995-09-20 GB GBGB9519197.9A patent/GB9519197D0/en active Pending
-
1996
- 1996-09-18 MY MYPI96003852A patent/MY127957A/en unknown
- 1996-09-19 KR KR1019980702097A patent/KR100537386B1/en not_active IP Right Cessation
- 1996-09-19 DE DE69634142T patent/DE69634142T2/en not_active Expired - Lifetime
- 1996-09-19 AT AT96930037T patent/ATE285827T1/en active
- 1996-09-19 CA CA2232626A patent/CA2232626C/en not_active Expired - Lifetime
- 1996-09-19 AU AU69242/96A patent/AU702901B2/en not_active Expired
- 1996-09-19 ES ES96930037T patent/ES2236748T3/en not_active Expired - Lifetime
- 1996-09-19 DK DK96930037T patent/DK0959975T3/en active
- 1996-09-19 ZA ZA967917A patent/ZA967917B/en unknown
- 1996-09-19 JP JP51233597A patent/JP4824147B2/en not_active Expired - Lifetime
- 1996-09-19 EP EP96930037A patent/EP0959975B1/en not_active Expired - Lifetime
- 1996-09-19 RU RU98107896/12A patent/RU2175261C2/en not_active IP Right Cessation
- 1996-09-19 WO PCT/DK1996/000399 patent/WO1997010887A1/en not_active Application Discontinuation
- 1996-09-19 CN CN96197849A patent/CN1089617C/en not_active Expired - Lifetime
- 1996-09-20 AR ARP960104427A patent/AR003634A1/en active IP Right Grant
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU98107896A (en) | NEW AFFINE LIGANDS AND THEIR APPLICATION | |
RU2175261C2 (en) | Novel affine ligands and their application | |
Ji | The application of chemical crosslinking for studies on cell membranes and the identification of surface reporters | |
US5739386A (en) | Photolabile compounds and methods for their use | |
US5053133A (en) | Affinity separation with activated polyamide microporous membranes | |
KR870000289A (en) | Method for preparing (meth) -acrylic acid derivatives of tricyclodecane | |
DE68924850D1 (en) | HETERO FUNCTIONAL CELLULAR IMMUNOLOGICAL REAGENTS, VACCINATES THEREOF AND METHOD OF USE. | |
DE59107974D1 (en) | Cell-free receptor binding tests, their production and use | |
KR850002469A (en) | Process for preparing the pisenadol precursor and intermediate thereof | |
KR910004069B1 (en) | Carrier for affinity chromatography immobilized with antibodies and preparation thereof | |
CA2477782C (en) | Polar silanes and their use on silica supports | |
SE8103198L (en) | PROCEDURE FOR PRODUCING ANTIBODIES | |
CN101171078A (en) | Affinity adsorbents for plasminogen | |
JPS61192342A (en) | Adsorbent | |
US20080093301A1 (en) | Disubstituted Cucurbituril-Bonded Silica Gel | |
US5015387A (en) | Method for activating cellulosic membrane, activated cellulosic membrane, method of fixing physiologically active substance on the activated cellulosic membrane and physiologically active substance-fixed membrane | |
EP0255717A3 (en) | Ganglioside related compounds and method of producing the same | |
JP2004531704A (en) | Chiral stationary phases based on derivatives of 4-amino-3,5-dinitrobenzoic acid | |
Raam et al. | The Presence of J-Chains in the Intracellular Fluid of IgM-Secreting Murine Tumor Cells | |
KR920701127A (en) | Chelating Agents for Attaching Metal Ions to Proteins | |
JP3051929B1 (en) | Method for producing pinacol compound | |
JPS6359891A (en) | Immobilization of substance | |
Stocks et al. | Second immunoaffinity ligands for cell separation | |
JPH09500210A (en) | Separation agent for hydrophobic chromatography | |
RU95117746A (en) | PASTERELLOSIS ANTIBODY ERYTHROCITAR DIAGNOSTICUM AND METHOD FOR PREPARING IT |